Helius Medical Technologies, Inc. - Class A Common Stock (HSDT)
9.5800
+0.00 (0.00%)
NASDAQ · Last Trade: Jul 22nd, 6:45 AM EDT
Detailed Quote
Previous Close
9.580
Open
-
Bid
10.20
Ask
10.29
Day's Range
N/A - N/A
52 Week Range
0.1701 - 24.00
Volume
16,073
Market Cap
35.72M
PE Ratio (TTM)
-3.032
EPS (TTM)
-3.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,085,782
Chart
About Helius Medical Technologies, Inc. - Class A Common Stock (HSDT)
Helius Medical Technologies is focused on developing and commercializing innovative medical devices aimed at improving treatment options for patients with neurological conditions, particularly those suffering from disorders resulting from traumatic brain injuries. The company's flagship product is designed to enhance the brain's natural ability to heal itself by leveraging neurotechnology. Helius is committed to advancing the field of neurology through rigorous scientific research and collaborations, ultimately aiming to improve outcomes and quality of life for affected individuals. Read More
Helius Medical Technologies Inc (NASDAQ:HSDT) shares are rising Monday after the company announced a positive outcome from the Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation.
NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC (the “Panel”) indicating that Helius has evidenced compliance with the equity requirement in Listing Rule 5550(b)(1) (the “Equity Rule”) for continued listing on the Nasdaq Capital Market.
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on June 30, 2025. Beginning on July 1, 2025, the Company’s common stock will trade on The Nasdaq Capital Market on a split adjusted basis.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
